These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20398326)

  • 1. Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ.
    Menn P; Weber N; Holle R
    Health Qual Life Outcomes; 2010 Apr; 8():39. PubMed ID: 20398326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations between disease-specific and generic health status questionnaires in patients with advanced COPD: a one-year observational study.
    Wilke S; Janssen DJ; Wouters EF; Schols JM; Franssen FM; Spruit MA
    Health Qual Life Outcomes; 2012 Aug; 10():98. PubMed ID: 22909154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease.
    Solem CT; Sun SX; Sudharshan L; Macahilig C; Katyal M; Gao X
    Int J Chron Obstruct Pulmon Dis; 2013; 8():641-52. PubMed ID: 24376348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of health-related quality of life measures in chronic obstructive pulmonary disease.
    Pickard AS; Yang Y; Lee TA
    Health Qual Life Outcomes; 2011 Apr; 9():26. PubMed ID: 21501522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities.
    Wacker ME; Jörres RA; Karch A; Wilke S; Heinrich J; Karrasch S; Koch A; Schulz H; Watz H; Leidl R; Vogelmeier C; Holle R;
    BMC Pulm Med; 2016 May; 16(1):70. PubMed ID: 27160582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?
    Rutten-van Mölken MP; Oostenbrink JB; Tashkin DP; Burkhart D; Monz BU
    Chest; 2006 Oct; 130(4):1117-28. PubMed ID: 17035446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validity of EQ-5D utility index and minimal clinically important difference estimation among patients with chronic obstructive pulmonary disease.
    Bae E; Choi SE; Lee H; Shin G; Kang D
    BMC Pulm Med; 2020 Mar; 20(1):73. PubMed ID: 32293387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison between the EQ-5D and the SF-6D in patients with chronic obstructive pulmonary disease (COPD).
    Chen J; Wong CK; McGhee SM; Pang PK; Yu WC
    PLoS One; 2014; 9(11):e112389. PubMed ID: 25379673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
    Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
    J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
    Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
    Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study.
    Tramontano AC; Schrag DL; Malin JK; Miller MC; Weeks JC; Swan JS; McMahon PM
    Med Decis Making; 2015 Apr; 35(3):371-87. PubMed ID: 25670839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measuring quality of life in COPD patients: comparing disease-specific supplements to the EQ-5D-5L.
    Szentes BL; Schwarzkopf L; Kirsch F; Schramm A; Leidl R
    Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):523-529. PubMed ID: 31512524
    [No Abstract]   [Full Text] [Related]  

  • 13. Estimating the burden of disease in chronic pain with and without neuropathic characteristics: does the choice between the EQ-5D and SF-6D matter?
    Torrance N; Lawson KD; Afolabi E; Bennett MI; Serpell MG; Dunn KM; Smith BH
    Pain; 2014 Oct; 155(10):1996-2004. PubMed ID: 25020004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between the EQ-5D-5L and exacerbations of chronic obstructive pulmonary disease in the ETHOS trial.
    Jackson D; Jenkins M; de Nigris E; Purkayastha D; Patel M; Ouwens M
    Qual Life Res; 2024 Apr; 33(4):1029-1039. PubMed ID: 38206455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do We Need to Assess Quality-of-Life with Both the St George's Respiratory Questionnaire and the EuroQol 5-Dimension Questionnaire in a Clinical Study with an Economic Component: Insights from the REVOLENS Study in Severe Emphysema.
    Bulsei J; Pfister J; Leroy S; Perotin JM; Barbe C; Marquette CH; Deslee G; Durand-Zaleski I;
    Int J Chron Obstruct Pulmon Dis; 2020; 15():135-142. PubMed ID: 32021152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure.
    Kontodimopoulos N; Argiriou M; Theakos N; Niakas D
    Eur J Health Econ; 2011 Aug; 12(4):383-91. PubMed ID: 20473544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between the EQ-5D-3L and the SF-6D quality of life (QOL) questionnaires in patients with chronic obstructive pulmonary disease (COPD) undergoing lung volume reduction surgery (LVRS).
    Thuppal S; Markwell S; Crabtree T; Hazelrigg S
    Qual Life Res; 2019 Jul; 28(7):1885-1892. PubMed ID: 30707368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of EQ-5D and SF-6D utilities in Pompe disease.
    Kanters TA; Redekop WK; Kruijshaar ME; van der Ploeg AT; Rutten-van Mölken MP; Hakkaart L
    Qual Life Res; 2015 Apr; 24(4):837-44. PubMed ID: 25342117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Psychometric Properties of EuroQoL 5-Dimension 5-Level and Short-Form 6-Dimension Utility Measures in Low Back Pain.
    Cheung PWH; Wong CKH; Cheung JPY
    Spine (Phila Pa 1976); 2019 Jun; 44(11):E679-E686. PubMed ID: 30475342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D.
    Szende A; Leidy NK; Ståhl E; Svensson K
    Qual Life Res; 2009 Mar; 18(2):267-72. PubMed ID: 19105049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.